



# Detection of Genes Involved in Biofilm Formation in MDR and XDR *Acinetobacter baumannii* Isolated from Human Clinical Specimens in Isfahan, Iran

Ahad Mahmoudi Monfared<sup>1</sup>, Aliakbar Rezaei<sup>1</sup>, Farkhondeh Poursina<sup>1</sup> and Jamshid Faghri<sup>1\*</sup>

<sup>1</sup>Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

\*Corresponding author: Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Tel: +98-9131148618, Email: faghri@med.ac.ir

Received 2018 October 26; Revised 2019 January 29; Accepted 2019 February 17.

## Abstract

**Background:** *Acinetobacter baumannii* is capable of forming biofilms that may be responsible for the survival of this pathogen in the hospital environment as well as antibiotic resistance.

**Objectives:** In this study, considering the importance of genes *bap*, *blaPER-1*, and *csuE* in the formation of biofilms and resistance to antimicrobial drugs, we aimed to investigate the frequency of these genes and also the relationship between these genes and the biofilm formation.

**Methods:** One hundred and eighteen clinical strains of the *A. baumannii* were collected and identified using standard microbiological methods. Antibiotic susceptibility was evaluated by microdilution broth and disk diffusion methods according to the Clinical and Laboratory Standards Institute (CLSI). Biofilm formation assay was performed by microtiter plate method. Then the *bap*, *blaPER-1*, and *csuE* genes were detected by PCR.

**Results:** The rate of XDR and MDR were 16.1% and 83.9%, respectively. Moreover, 9 (7.6%) isolates were resistant to colistin. The results of biofilm formation revealed that 32 (27.1%), 33 (28.0%), 37 (31.4%), and 16 (13.6%) of the isolates had non-biofilm, weak, moderate, and strong activities, respectively. The association between the formation of biofilm and amikacin resistance was found ( $P < 0.05$ ). In the isolates, the frequencies of *bap*, *blaPER-1*, and *csuE* genes were 70.3%, 54.2%, and 93.2%, respectively. Statistical analysis showed a significant correlation between the frequency of *blaPER-1* and *bap* genes and the ability to form biofilms ( $P < 0.05$ ).

**Conclusions:** This study shows the high tendency among the clinical isolates of *A. baumannii* to form a biofilm. It also shows the correlation between the presence of *blaPER-1* and *bap* genes with the capacity of biofilm formation. Moreover, the majority (92.4%) of the *A. baumannii* isolates from Isfahan were susceptible to colistin. Therefore, providing new and effective strategies is essential for the prevention and treatment of infections caused by biofilm-forming *A. baumannii* strains.

**Keywords:** *Acinetobacter baumannii*, Biofilm, Antibiotic Resistance

## 1. Background

*A. baumannii* is a non-motile, oxidase-negative, aerobic, and non-fermenting Gram-negative coccobacillus that is mostly seen among hospitalized patients, especially in the intensive care units (ICU) (1). This organism creates a wide range of infections such as ventilator-associated pneumonia (VAP), pneumonia, endocarditis, skin infections, bacteremia, wound infection, urinary tract infection, and meningitis (2). In different species of *Acinetobacter*, the acquisition and dissemination of a drug-resistant determinant in community and hospitals are greatly facilitated by horizontal gene transfer of genetic mobile elements such as transposons, plasmids, and integrons. Among these genetic mobile elements, integrons are important because of

their capacity for expressing and carrying resistance genes (3). Recently, due to the high use of antibiotics, extensive antibiotic resistant and multidrug-resistant *A. baumannii* (XDR-AB, and MDR-AB) have emerged as a major problem worldwide (1).

The use of broad-spectrum antibiotics, as well as the transmission of strains among patients, created a selective pressure that led to the emerging of MDR-AB (4). The most important challenge for clinical microbiologists and physicians is the management of MDR *Acinetobacter* spp. infections. Ability to survive in clinical settings makes it a common agent for healthcare-associated infections which leads to multiple outbreaks. Spectrums of infections due to MDR *Acinetobacter* spp. contain pneumonia, UTI, bacteremia, wound infection, and meningitis. *A. baumannii* is

intrinsically resistant to antibiotic agents, which is due to the expression of active efflux pump systems; the low expression of outer membrane porins; having a resistance island, which contains a cluster of genes encoding antibiotic; and heavy metal resistance, which causes resistance to ammonium-based disinfectants (5).

*A. baumannii* shows several mechanisms to resist multiple antibiotic classes, including the production of antibiotic degradation/modification enzymes, decreased permeability, active drug efflux pumps, modification in drug targets, and biofilm formation (6). It is also difficult to control *A. baumannii* because it can survive in hospital settings for a long time. The potential of *A. baumannii* to demonstrate multiple antibiotic resistance and biofilm formation may be involved in the ability to survive in the environment (7). Biofilm formation on all surfaces is a good strategy for increasing the chances of bacterial survival in stressful conditions following environmental conditions or antibiotic treatment (6, 7). Increasing the synthesis of exopolysaccharides and also the development of drug resistance are sometimes associated with biofilm production (8). Many factors are involved in the formation of biofilms, including outer membrane protein A (OmpA), biofilm-associated protein (*Bap*), beta-lactamase *PER-1*, iron uptake mechanism, and the *CsuA/BABCDE* chaperone-usher pili assembly system (9). Some surface proteins such as *ompA*, *blaPER-1*, and *Bap*, in addition to being involved in biofilm formation, are also involved in the bacterial attachment to human epithelial cells and abiotic surfaces (10).

The expression of the *CsuA/BABCDE* chaperon-usher complex is needed for the assembly and production of pili contributing to adhesion to abiotic surfaces (11). It has been shown that inactivation of the *csuE* gene inhibits the production of pili as well as biofilm formation (12). The expression of *csu* operon is controlled by a two-component regulatory system, including a response regulator encoded by *bfmR* and a sensor kinase encoded by *bfmS*. Translational and transcriptional analyses show that the inactivation of *bfmR* prevents the expression of this operon and the consequent inactivation of both pili production and biofilm formation (13). In addition, the *blaPER-1* gene is also associated with increased biofilm formation and increased bacterial attachment to the abiotic surfaces and human epithelial cells (10).

## 2. Objectives

Because of the importance of genes *blaPER-1* and *csuE* in cell adhesiveness and pili production, as well as the formation of biofilms and ultimately antibiotic resistance, we aimed to investigate the prevalence of these genes in

the clinical strains of Isfahan and the association of these genes with biofilm production.

## 3. Methods

### 3.1. Collection and Identification of Bacterial Isolates

In this cross-sectional study, based on Equation 1

$$n = \frac{z^2 p (1 - p)}{d^2} \quad (1)$$

where d: 0.09, p: 0.533, and z: 1.96 (1), one hundred and eighteen *A. baumannii* isolates were collected from October 2017 to June 2018 at three educational hospitals affiliated to Isfahan University of Medical Sciences Isfahan, Iran. The isolates were collected from different clinical samples such as sputum, endotracheal aspirates, urine, blood, aspirates, intravenous catheters, wound, tissues and cerebrospinal fluid (CSF) of the patients hospitalized to different wards in educational hospitals (Al-Zahra, Imam Mousa Kazem, and Shariati) in Isfahan, Iran. The samples were cultured on standard laboratory media such as MacConkey agar and blood agar (Merck, Germany) and incubated overnight at 37°C. Primary identification was performed by conventional biochemical tests and was also confirmed by the PCR method for *blaOXA-51* gene as previously explained (14).

### 3.2. Antimicrobial Susceptibility Tests

#### 3.2.1. Disk Diffusion

The antimicrobial Susceptibility testing was performed based on Kirby-Bauer disk diffusion method according to Clinical Laboratory Standard Institute guidelines (CLSI) (15) against meropenem (10 µg), imipenem (10 µg), ciprofloxacin (5 µg), ceftazidime (30 µg), gentamicin (10 µg), doxycycline (30 µg), piperacillin-tazobactam (100/10 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), cefepime (30 µg), amikacin (30 mg), and tetracycline (30 mg) disks (Mast Group Co, UK). *Escherichia coli* ATCC 25922 was used as a quality control strain for antibiotic disks in susceptibility testing (15).

#### 3.2.2. Minimal Inhibitory Concentration (MIC)

A microbroth dilution assay was used to determine MICs of imipenem and colistin (Sigma-Aldrich, St Louis, MO, USA) according to CLSI (15). Serial concentrations of imipenem and colistin were used (from 256 to 0.25 µg/mL). The last well where turbidity was not observed was considered MIC. *Escherichia coli* ATCC 25922 was used as a quality control strain.

### 3.3. Biofilm Production Assay

The *A. baumannii* isolates were analyzed for their ability to biofilm production using microtiter dish biofilm formation assay with 0.1% crystal violet according to the instructions described (16). The absorbance of each well was measured at 560 nm using an ELISA reader. For each isolate, the assay was repeated at least three times. Uninoculated wells containing media were used as a control (16). Based on the optical density of the samples (ODi) and also on the average of the optical density of the negative control (ODc), the isolates were classified as follow: if  $ODi < ODc$ , the bacteria were non-adherent; if  $ODc < ODi \leq 2xODc$ , the bacteria were weakly adherent; if  $2xODc < ODi \leq 4xODc$ , the bacteria were moderately adherent; and if  $4xODc < ODi$ , the bacteria were strongly adherent (16).

### 3.4. Detection of Biofilm-Related Genes (*csuE*, *bap*, and *blaPER-1*)

The bacterial genome was extracted using boiling method, as described previously (17). The PCR assays were performed by the primers shown in Table 1 to determine the presence of *csuE*, *bap*, and *blaPER-1* genes. The conditions for PCR amplification were initial denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 45 seconds, primer annealing at 59°C for *blaPER-1*, 48°C for *csuE* and 57°C for *bap* for 45 seconds, and extension at 72°C for 50 seconds, and a final extension at 72°C for 6 minutes. *P. aeruginosa* containing *blaPER-1* received from Pasteur Institute, France, was used as the positive control.

### 3.5. Statistical Analysis

Statistical analysis was performed using software IBM SPSS Statistics version 25.0 (IBM Corp., USA). The association between genes involved in biofilm formation and also the amount of biofilm formation with antibiotic resistance phenotypes of *A. baumannii* was evaluated by chi-square and Fisher's exact tests. The total frequencies of biofilm-related genes were measured in isolates and their relationship to biofilm formation was analyzed using multinomial logistic regression test. The analysis was performed with a confidence level of 95%. P values < 0.05 were considered statistically significant.

## 4. Results

During the 9-month period of study 118 clinical isolates of *A. baumannii* were collected. Overall, 79 (66.9%) isolates were obtained from male and 39 (33.1%) from female samples. Sixty-three *A. baumannii* isolates (53.4%) were recovered from tracheal aspirate, followed by 13 (11.0%) from wounds, 7 (5.9%) from CSF, 9 (7.6%) from sputum, 4 (3.4%)

from blood, 2 (1.7%) from catheters, and 20 (17.1%) from other samples.

Antibiotic resistance was severe among the isolates. One hundred and nine (92.4%) of isolates were susceptible to colistin and all isolates were resistant to imipenem. Among 118 isolates, 16.1% (19/118) of *A. baumannii* isolates were identified as XDR and 83.9% (99/118) of isolates were MDR. Table 2 shows an antibiotic resistance pattern of the *A. baumannii* isolates. The MIC of *A. baumannii* isolates is shown in Table 2. The range of MIC for colistin in isolates was ranged from 0.25 to 8 mg/mL and 92.4% of them were susceptible to colistin. According to results, 100% of isolates were resistant to imipenem. The majority of imipenem-resistant *A. baumannii* isolates exhibited a MIC  $\geq 256 \mu\text{g/mL}$  (Table 3).

The majority of isolates were able to form varying degrees of biofilm. The mean optical densities for isolates were  $0.306 \pm 0.018$  (ranged from 0.052 to 1.046). Based on the results, biofilm formation capabilities of the isolates were classified as non-biofilm, weak, moderate, and strong biofilm producer that 32 (27.1%), 33 (28.0%), 37 (31.4%), and 16 (13.6%) isolates had non-biofilm, weak, moderate, and strong-adherence activity in the microplate assay, respectively. In all (100%) isolates, the *blaOXA-51* gene was detected and confirmed the *A. baumannii*. In the 118 isolates, the detection rates of *bap*, *csuE*, and *bla-PER1* were 70.3%, 93.2%, and 54.2%, respectively (Table 4). The mean for biofilm biomass in *bap*, *csuE*, and *blaPER-1* positive isolates were  $0.356 \pm 0.210$ ,  $0.308 \pm 0.198$ , and  $0.359 \pm 0.234$ , respectively.

Statistical analysis revealed a significant correlation between the frequency of *blaPER-1* positive strains and biofilm formation in all isolates ( $P < 0.05$ ). The results showed that 70.3% (83 cases) of *A. baumannii* isolates encoded *bap* gene and 93.2% of the isolates encoded *csuE* gene that the presence of *bap* gene is associated with biofilm formation ( $P \leq 0.001$ ), but no significant correlation was seen between the presence of *csuE* gene and biofilm formation. There was a significant association between biofilm-forming ability and amikacin resistance ( $P < 0.05$ ).

## 5. Discussion

*A. baumannii* is an opportunistic pathogen that can colonize the skin, oral cavities, respiratory tract, conjunctiva, urinary tract, and gastrointestinal tract. Nosocomial infections of this pathogen are generally transmitted directly from health-care workers or via environmental surfaces to patients because of the ability of this organism to survive in the environment for a long time (20, 21). *A. baumannii* colonization has been reported commonly from ICU and

**Table 1.** The Primers Used in This Study for Detection of *bla* OXA-51 Gene and Biofilm-Related Genes

| Genes           | Amplicon Size, bp | Sequences                      | Reference |
|-----------------|-------------------|--------------------------------|-----------|
| <i>Oxa51</i>    | 353               | 5-TAA TGC TTT GAT CGG CCT TG-3 | (14)      |
|                 |                   | 5-TGG ATT GCA CTT CAT CTT GG-3 |           |
| <i>blaPER-1</i> | 340               | 5-GCAACTGCTGCAATACTCGG-3       | (18)      |
|                 |                   | 5-ATGTGCGACCACAGTACCAG-3       |           |
| <i>bap</i>      | 184               | 5-TGCTGACAGTGACGTAGAACCACA-3   | (1)       |
|                 |                   | 5-TGCAACTAGTGGAAATAGCAGCCCA-3  |           |
| <i>csuE</i>     | 168               | 5-CATCTTCTATTTCGGTCCC-3        | (19)      |
|                 |                   | 5-CGGTCTGAGCATTGGTAA-3         |           |

**Table 2.** Antimicrobial Susceptibilities of the *Acinetobacter baumannii* Isolates (N = 118)<sup>a</sup>

| Antibiotic                    | Susceptible | Intermediate | Resistant  |
|-------------------------------|-------------|--------------|------------|
| Meropenem                     | 1 (0.8)     | 0 (0.0)      | 117 (99.2) |
| Imipenem                      | 0 (0)       | 0 (0.0)      | 118 (100)  |
| Ciprofloxacin                 | 1 (0.8)     | 0 (0.0)      | 117 (99.2) |
| Ceftazidime                   | 2 (1.7)     | 0 (0.0)      | 116 (98.3) |
| Gentamicin                    | 5 (4.2)     | 0 (0.0)      | 113 (95.8) |
| Tetracycline                  | 7 (5.9)     | 20 (16.9)    | 91 (77.2)  |
| Doxycycline                   | 5 (4.2)     | 0 (0.0)      | 113 (95.8) |
| Piperacillin-tazobactam       | 1 (0.8)     | 0 (0.0)      | 117 (99.2) |
| Trimethoprim-sulfamethoxazole | 2 (1.7)     | 0 (0.0)      | 116 (98.3) |
| Cefepime                      | 1 (0.8)     | 0 (0.0)      | 117 (99.2) |
| Amikacin                      | 9 (7.6)     | 11 (9.3)     | 98 (83.1)  |

<sup>a</sup>Values are expressed as No. (%).

surgical wards, where most of nosocomial infections occurred (22). In order to effectively control the infection in hospitals, particularly in ICU, the main parameters should be evaluated to provide useful and practical approaches that they could be used as a strategic plan for infection control committees. Physicians should also use this information to achieve effective therapies, combat antibiotic resistance, reduce medical costs, and reduce mortality. For this purpose, the current study was designed to evaluate different parameters (i.e. the ability of biofilm production, the frequency of biofilm-related genes, etc.) and considering the importance of *bap*, *blaPER-1*, and *csuE* genes in cell adhesion and contribution to the formation of pili, respectively. In addition, biofilm production and resistance to antimicrobial drugs were also investigated.

In this study, we observed that *A. baumannii* isolates were resistant to drugs commonly used to treat *A. baumannii*. Moreover, 16.1% of isolates were XDR and 83.9% were

MDR. Antibiogram and MIC tests showed that the resistance of isolates to many antibiotics was more than 90% and they were just sensitive against colistin that out of 118 isolates, 9 isolates were resistant to colistin, and since there are no new drugs for this infection and as an alternative to existing drugs, as well as there is no vaccine against this infection, the only way to eliminate the effects of infection is to control their spread. In our study, the prevalence of colistin-resistant *A. baumannii* was 7.6%, while in previous studies it was 0% (23), 6% (24), and 12% (25). Although resistance to colistin has been reported in our study, this drug is the most effective and best option for treating this infection.

Among various virulence factors, the ability to form biofilm is one of the most important factors involved in the pathogenicity of *A. baumannii* (12). The present study proved that 72.9% of isolates were able to form biofilms (in varying degrees), which had a lower rate than other studies. In a study conducted by Bardbari et al. in Hamadan, almost 100% of isolates were able to form biofilms (1). Also, in a study conducted by Vijayakumar et al. in India, all isolates were also able to form biofilms (12). The frequency of genes involved in biofilm formation was largely similar to other studies (1, 19, 26, 27).

Most of *Acinetobacter* isolates encoded *bap* gene. The presence of this gene in isolates was significantly associated with the ability of biofilm formation ( $P < 0.001$ ). Azizi et al. (19) and Sung et al. (28) showed that the ability to form a biofilm in *A. baumannii* isolates carrying the *bap* gene was significantly different from isolates that lack this gene. Our observations also confirmed the important role of *bap* gene in biofilm formation. In a study by Bardbari et al. in 2016 in Hamadan (1), there was no significant relationship between biofilm formation and *blaPER-1* gene, while there was a positive correlation between the existence of this gene and biofilm formation in the present study ( $P < 0.05$ ).

The data from our study is used to improve the disin-

**Table 3.** The MIC of *A. baumannii* Isolates Against Colistin and Imipenem<sup>a</sup>

| Antibiotic | Breakpoint, $\mu\text{g/mL}$              | Susceptible | Intermediate | Resistant |
|------------|---|-------------|--------------|-----------|
| Colistin   | Susceptible $\leq 2$ , resistant $\geq 4$ | 109 (92.4)  | 0 (0.0)      | 9 (7.6)   |
| Imipenem   | Susceptible $\leq 2$ , resistant $\geq 8$ | 118 (100)   | 0 (0.0)      | 0 (0.0)   |

<sup>a</sup>Values are expressed as No. (%).

**Table 4.** Biofilm-Related Gene Expression and Biofilm Intensity in Clinical Isolates of *A. baumannii*

| Biofilm Intensity    | Biofilm-Related Genes |                 |             |
|----------------------|-----------------------|-----------------|-------------|
|                      | <i>bap</i>            | <i>blaPER-1</i> | <i>csuE</i> |
| Strong (n = 16)      | 16                    | 12              | 14          |
| Moderate (n = 37)    | 36                    | 29              | 36          |
| Weak (n = 33)        | 31                    | 14              | 29          |
| Non-biofilm (n = 32) | 0                     | 9               | 31          |
| Total (n = 118)      | 83                    | 64              | 110         |

fection methods for controlling infectious diseases. Therefore, expanding the knowledge of the mechanisms that lead to biofilm production as well as the development of antibiotic resistance will allow us to treat or control biofilm-related infections. The limitation of our study was that only clinical specimens were used and environmental samples were not studied, which may affect the outcome of the observation. In this study, the genes *ompA* and *abaI* that could be involved in biofilm formation were not investigated. Therefore, the relationship between the presence of these genes and the rate of biofilm formation is suggested for future studies.

### 5.1. Conclusions

Most isolates were able to form biofilms. There was a significant correlation between the presence of *bap* and *blaPER-1* genes in the *A. baumannii* isolates and the ability to form biofilms. This research provides information on the characteristics of clinical isolates, such as resistance to antibiotic agents and biofilm formation that improve our understanding of how to control the infection.

### Acknowledgments

This investigation is a part of M.Sc. thesis of Mr. Ahad Mahmoudi Monfared. The authors would like to acknowledge Dr. Akbar Hasan Zadeh from the Department of Epidemiology and Biostatistics of the Isfahan University of Medical Sciences for statistical advice.

### Footnotes

**Authors' Contribution:** Ahad Mahmoudi Monfared: author; Jamshid Faghri: corresponding author; Farkhondeh Poursina: review of the article; Aliakbar Rezaei: contribution to the plan.

**Conflict of Interests:** None of the authors have any conflicts of interest.

**Funding/Support:** This research was funded by the vice-chancellor of research and technology of Isfahan University of Medical Sciences (grant No. 396758).

### References

- Bardbari AM, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental *Acinetobacter baumannii* isolates. *Microb Pathog.* 2017;**108**:122-8. doi: [10.1016/j.micpath.2017.04.039](https://doi.org/10.1016/j.micpath.2017.04.039). [PubMed: 28457900].
- Rezaei A, Fazeli H, Halaji M, Moghadampour M, Faghri J. Prevalence of metallo-beta-lactamase producing *Acinetobacter baumannii* isolated from intensive care unit in tertiary care hospitals. *Ann Ig.* 2018;**30**(4):330-6. doi: [10.7416/ai.2018.2224](https://doi.org/10.7416/ai.2018.2224). [PubMed: 29895050].
- Fallah F, Karimi A, Goudarzi M, Shiva F, Navidinia M, Jahromi MH, et al. Determination of integron frequency by a polymerase chain reaction-restriction fragment length polymorphism method in multidrug-resistant *Escherichia coli*, which causes urinary tract infections. *Microb Drug Resist.* 2012;**18**(6):546-9. doi: [10.1089/mdr.2012.0073](https://doi.org/10.1089/mdr.2012.0073). [PubMed: 22816551].
- Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis.* 2008;**46**(8):1254-63. doi: [10.1086/529198](https://doi.org/10.1086/529198). [PubMed: 18444865].
- Navidinia M, Goudarzi M, Molaei Rameshe S, Farajollahi Z, Ebadi Asl P, Zaka Khosravi S, et al. Molecular characterization of resistance genes in MDR-ESKAPE pathogens. *J Pure Appl Microbiol.* 2017;**11**(2):779-92. doi: [10.22207/jpam.11.2.17](https://doi.org/10.22207/jpam.11.2.17).
- Surung J, Khyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhat-tacharyya P. Association of biofilm production with multidrug resistance among clinical isolates of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* from intensive care unit. *Indian J Crit Care Med.* 2013;**17**(4):214-8. doi: [10.4103/0972-5229.118416](https://doi.org/10.4103/0972-5229.118416). [PubMed: 24133328]. [PubMed Central: PMC3796899].
- Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of *Acinetobacter baumannii*. *Am J Infect Control.* 2016;**44**(5):e65-71. doi: [10.1016/j.ajic.2015.12.012](https://doi.org/10.1016/j.ajic.2015.12.012). [PubMed: 26851196].
- Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. *Science.* 1999;**284**(5418):1318-22. doi: [10.1126/science.284.5418.1318](https://doi.org/10.1126/science.284.5418.1318). [PubMed: 10334980].



9. Gaddy JA, Actis LA. Regulation of *Acinetobacter baumannii* biofilm formation. *Future Microbiol.* 2009;**4**(3):273-8. doi: [10.2217/fmb.09.5](https://doi.org/10.2217/fmb.09.5). [PubMed: [19327114](https://pubmed.ncbi.nlm.nih.gov/19327114/)]. [PubMed Central: [PMC2724675](https://pubmed.ncbi.nlm.nih.gov/PMC2724675/)].
10. Brossard KA, Campagnari AA. The *Acinetobacter baumannii* biofilm-associated protein plays a role in adherence to human epithelial cells. *Infect Immun.* 2012;**80**(1):228-33. doi: [10.1128/IAI.05913-11](https://doi.org/10.1128/IAI.05913-11). [PubMed: [22083703](https://pubmed.ncbi.nlm.nih.gov/22083703/)]. [PubMed Central: [PMC3255684](https://pubmed.ncbi.nlm.nih.gov/PMC3255684/)].
11. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by *Acinetobacter baumannii*: Involvement of a novel chaperone-usher pili assembly system. *Microbiology.* 2003;**149**(Pt 12):3473-84. doi: [10.1099/mic.0.26541-0](https://doi.org/10.1099/mic.0.26541-0). [PubMed: [14663080](https://pubmed.ncbi.nlm.nih.gov/14663080/)].
12. Vijayakumar S, Rajenderan S, Laishram S, Anandan S, Balaji V, Biswas I. Biofilm formation and motility depend on the nature of the *Acinetobacter baumannii* clinical isolates. *Front Public Health.* 2016;**4**:105. doi: [10.3389/fpubh.2016.00105](https://doi.org/10.3389/fpubh.2016.00105). [PubMed: [27252939](https://pubmed.ncbi.nlm.nih.gov/27252939/)]. [PubMed Central: [PMC4877508](https://pubmed.ncbi.nlm.nih.gov/PMC4877508/)].
13. Tomaras AP, Flagler MJ, Dorsey CW, Gaddy JA, Actis LA. Characterization of a two-component regulatory system from *Acinetobacter baumannii* that controls biofilm formation and cellular morphology. *Microbiology.* 2008;**154**(Pt 11):3398-409. doi: [10.1099/mic.0.2008/019471-0](https://doi.org/10.1099/mic.0.2008/019471-0). [PubMed: [18957593](https://pubmed.ncbi.nlm.nih.gov/18957593/)].
14. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol.* 2006;**44**(8):2974-6. doi: [10.1128/JCM.01021-06](https://doi.org/10.1128/JCM.01021-06). [PubMed: [16891520](https://pubmed.ncbi.nlm.nih.gov/16891520/)]. [PubMed Central: [PMC1594603](https://pubmed.ncbi.nlm.nih.gov/PMC1594603/)].
15. Patel JB. *Performance standards for antimicrobial susceptibility testing.* Clinical and Laboratory Standards Institute; 2017.
16. Ghanbarzadeh Corehtash Z, Khorshidi A, Firoozeh F, Akbari H, Mahmoudi Aznaveh A. Biofilm formation and virulence factors among *Pseudomonas aeruginosa* isolated from burn patients. *Jundishapur J Microbiol.* 2015;**8**(10). e22345. doi: [10.5812/jjm.22345](https://doi.org/10.5812/jjm.22345). [PubMed: [26587205](https://pubmed.ncbi.nlm.nih.gov/26587205/)]. [PubMed Central: [PMC4644346](https://pubmed.ncbi.nlm.nih.gov/PMC4644346/)].
17. Ahmed OB, Dablood AS. Quality improvement of the DNA extracted by boiling method in gram negative bacteria. *Int J Bioassays.* 2017;**6**(4):5347-9. doi: [10.21746/ijbio.2017.04.004](https://doi.org/10.21746/ijbio.2017.04.004).
18. Fallah F, Noori M, Hashemi A, Goudarzi H, Karimi A, Erfanimanesh S, et al. Prevalence of bla NDM, bla PER, bla VEB, bla IMP, and bla VIM genes among *acinetobacter baumannii* isolated from two hospitals of Tehran, Iran. *Scientifica (Cairo).* 2014;**2014**:245162. doi: [10.1155/2014/245162](https://doi.org/10.1155/2014/245162). [PubMed: [25133013](https://pubmed.ncbi.nlm.nih.gov/25133013/)]. [PubMed Central: [PMC4123593](https://pubmed.ncbi.nlm.nih.gov/PMC4123593/)].
19. Azizi O, Shahcheraghi F, Salimizand H, Modarresi F, Shakibaie MR, Mansouri S, et al. Molecular analysis and expression of bap gene in biofilm-forming multi-drug-resistant *Acinetobacter baumannii*. *Rep Biochem Mol Biol.* 2016;**5**(1):62-72. [PubMed: [28070537](https://pubmed.ncbi.nlm.nih.gov/28070537/)]. [PubMed Central: [PMC5214686](https://pubmed.ncbi.nlm.nih.gov/PMC5214686/)].
20. Borer A, Gilad J, Smolyakov R, Eskira S, Peled N, Porat N, et al. Cell phones and *Acinetobacter* transmission. *Emerg Infect Dis.* 2005;**11**(7):1160-1. doi: [10.3201/eid1107.050221](https://doi.org/10.3201/eid1107.050221). [PubMed: [16032803](https://pubmed.ncbi.nlm.nih.gov/16032803/)]. [PubMed Central: [PMC3371817](https://pubmed.ncbi.nlm.nih.gov/PMC3371817/)].
21. Munoz-Price LS, Weinstein RA. *Acinetobacter* infection. *N Engl J Med.* 2008;**358**(12):1271-81. doi: [10.1056/NEJMra070741](https://doi.org/10.1056/NEJMra070741). [PubMed: [18354105](https://pubmed.ncbi.nlm.nih.gov/18354105/)].
22. Daef EA, Mohamad IS, Ahmad AS, El-Gendy SG, Ahmed EH, Sayed IM. Relationship between clinical and environmental isolates of *Acinetobacter baumannii* in Assiut university hospitals. *J Am Sci.* 2013;**9**(11s):67-73.
23. Asadollahi P, Akbari M, Soroush S, Taherikalani M, Asadollahi K, Sayehmiri K, et al. Antimicrobial resistance patterns and their encoding genes among *Acinetobacter baumannii* strains isolated from burned patients. *Burns.* 2012;**38**(8):1198-203. doi: [10.1016/j.burns.2012.04.008](https://doi.org/10.1016/j.burns.2012.04.008). [PubMed: [22579564](https://pubmed.ncbi.nlm.nih.gov/22579564/)].
24. Sepahvand S, Doudi M, Davarpanah MA, Bahador A, Ahmadi M. Analyzing pmrA and pmrB genes in *Acinetobacter baumannii* resistant to colistin in Shahid Rajai Shiraz, Iran Hospital by PCR: First report in Iran. *Pak J Pharm Sci.* 2016;**29**(4 Suppl):1401-6. [PubMed: [27592491](https://pubmed.ncbi.nlm.nih.gov/27592491/)].
25. Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. *Iran J Microbiol.* 2011;**3**(2):68-74. [PubMed: [22347585](https://pubmed.ncbi.nlm.nih.gov/22347585/)]. [PubMed Central: [PMC3279807](https://pubmed.ncbi.nlm.nih.gov/PMC3279807/)].
26. Badmasti F, Siadat SD, Bouzari S, Ajdary S, Shahcheraghi F. Molecular detection of genes related to biofilm formation in multidrug-resistant *Acinetobacter baumannii* isolated from clinical settings. *J Med Microbiol.* 2015;**64**(Pt 5):559-64. doi: [10.1099/jmm.0.000058](https://doi.org/10.1099/jmm.0.000058). [PubMed: [25813817](https://pubmed.ncbi.nlm.nih.gov/25813817/)].
27. Liu H, Wu YQ, Chen LP, Gao X, Huang HN, Qiu FL, et al. Biofilm-related genes: Analyses in multi-antibiotic resistant *Acinetobacter baumannii* isolates from Mainland China. *Med Sci Monit.* 2016;**22**:1801-7. doi: [10.12659/MSM.898959](https://doi.org/10.12659/MSM.898959). [PubMed: [27234982](https://pubmed.ncbi.nlm.nih.gov/27234982/)]. [PubMed Central: [PMC4913728](https://pubmed.ncbi.nlm.nih.gov/PMC4913728/)].
28. Sung JY, Koo SH, Kim S, Kwon GC. Persistence of multidrug-resistant *Acinetobacter baumannii* isolates harboring blaOXA-23 and bap for 5 years. *J Microbiol Biotechnol.* 2016;**26**(8):1481-9. doi: [10.4014/jmb.1604.04049](https://doi.org/10.4014/jmb.1604.04049). [PubMed: [27221112](https://pubmed.ncbi.nlm.nih.gov/27221112/)].